High Net Worth Advisory Group’s Arcturus Therapeutics ARCT Stock Holding History

High Net Worth Advisory Group’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,500	Closed	-$22K	–	631
2022 Q3	$22K	Hold	1,500	–	–	0.01%	436
2022 Q2	$24K	Hold	1,500	–	–	0.01%	417
2022 Q1	$40K	Hold	1,500	–	–	0.01%	366
2021 Q4	$56K	Buy	+1,500	New	+$61.1K	0.02%	333

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

High Net Worth Advisory Group's ARCT Position: Q4 2022 in Review

High Net Worth Advisory Group sold out of Arcturus Therapeutics (ARCT) in Q4 2022, closing a stake of 1,500 shares — an estimated $22K sold.

High Net Worth Advisory Group first reported a position in ARCT in Q4 2021 and held it in 4 quarters. The position peaked at $56K in Q4 2021. 111 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

High Net Worth Advisory Group reported no remaining Arcturus Therapeutics position as of Q4 2022 after selling out during the quarter.
High Net Worth Advisory Group sold 1,500 Arcturus Therapeutics shares in Q4 2022, an estimated $22K.
High Net Worth Advisory Group first reported a position in Arcturus Therapeutics in Q4 2021 and held it in 4 quarters.
High Net Worth Advisory Group's Arcturus Therapeutics position peaked at $56K in Q4 2021.
111 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on High Net Worth Advisory Group's 13F filing for Q4 2022, filed 14 Feb 2023.